Publication Name	World Journal of Gastroenterology
Manuscript ID	2473
Country	United Kingdom

Received	2013-02-22 14:40
Peer-Review Started	2013-02-26 08:54
To Make the First Decision	2013-03-04 13:43
Return for Revision	2013-03-06 18:24
Revised	2013-03-26 22:25
Second Decision	2013-06-18 10:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-19 00:21
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-18 15:53
Publish the Manuscript Online	2013-08-06 09:19

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Aravind Suppiah and John Greenman
Funding Agency and Grant Number
Corresponding Author	Aravind Suppiah, MD, FRCS, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, United Kingdom. aravind.suppiah@hotmail.com
Key Words	p53 gene; p53 mutation; Anti-p53 auto-antibody; Cancer; Colorectal cancer
Core Tip	Anti-p53 auto-antibodies are commonly produced in response to p53 mutations. Anti-p53 auto-antibody titres generally increase with tumour load, but not all patients who are initially sero-negative develop an auto-antibody response despite disease progression and metastases. Conversely, sero-positive patients do not lose their anti-p53 auto-antibodies despite the cancer being completely excised. In general, cancers with the highest p53 mutation rate, e.g., oesophageal and ovarian, demonstrate the highest anti-p53 auto-antibody rates; conversely, melanoma and testicular carcinoma with the lowest mutation rate have the lowest serum auto-antibody levels. Measurement of anti-p53 auto-antibodies may be useful in screening or monitoring for tumour recurrence.
Publish Date	2013-08-06 09:19
Citation	Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer. World J Gastroenterol 2013; 19(29): 4651-4670
URL	http://www.wjgnet.com/1007-9327/full/v19/i29/4651.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i29.4651

Full Article (PDF)	WJG-19-4651.pdf
Manuscript File	2473-Review.doc
Answering Reviewers	2473-Answering reviewers.doc
Copyright License Agreement	2473-Copyright assignment.pdf
Peer-review Report	2473-Peer review(s).pdf
Scientific Editor Work List	2473-Scientific editor work list.doc